69480-03-1

Upstream product

• 78-82-0 Isobutyronitrile 
• 88-03-9 2,4,6-trihydroxytoluene 
• 79-30-1 isobutyryl chloride 
• 108-73-6 3,5-dihydroxyphenol 
• 487-70-7 2,4,6-trihydroxybenzaldehyde 

Downstream Products

• 99174-42-2 2.4.4'.6'-Tetrahydroxy-6.2'-dimethoxy-3.3'-dimethyl-5.5'-di-isobutyryl-diphenylmethan 
• 99174-41-1 2.6.4'.6'-Tetrahydroxy-4.2'-dimethoxy-3.3'-dimethyl-5.5'-di-isobutyryl-diphenylmethan 
• 99174-40-0 bis-(2,4-dihydroxy-3-isobutyryl-6-methoxy-5-methyl-phenyl)-methane 
• 93903-80-1 3-Methyl-phlor-isobutyrophenon-4-benzylaether 
• 479-88-9 4,6-Dimethoxy-2-hydroxy-3-methyl-isobutyrophenon 
• 42541-64-0 2,6-Dihydroxy-4-methoxy-3-methyl-isopropiophenone 

Relevant academic research and scientific papers

Biomimetic total syntheses of baefrutones A-D, baeckenon B, and frutescones A, D-F

Biomimetic total syntheses of baefrutones A-D (1-4), baeckenon B (5), and frutescones A, D-F (6-9), isolated from the leaves of Baeckea frutescens, were achieved in 9, 8, and 5 steps, respectively, in moderate to good yields (72-83%). The synthetic routes feature the Michael addition, oxidative [4 + 2] cycloaddition, and water-promoted Diels-Alder click reactions as the key steps. This study helped gain thorough mechanistic insights into the biosynthetic origins and provided a facile approach for the construction of a library of natural tasmanone-based meroterpenoid analogues. Moreover, compounds 1-9 show potent inhibitory effects against S. paratyphi and/or C. albicans with MIC values of 3.125-25 μg mL-1, and they could be promising lead molecules for the design of new antibiotic agents.

Derivatives of Natural Product Agrimophol as Disruptors of Intrabacterial pH Homeostasis in Mycobacterium tuberculosis

This article reports the rational medicinal chemistry of a natural product, agrimophol (1), as a new disruptor of intrabacterial pH (pHIB) homeostasis in Mycobacterium tuberculosis (Mtb). Through the systematic investigation of the structure-activity relationship of 1, scaffold-hopping of the diphenylmethane scaffold, pharmacophore displacement strategies, and studies of the structure-metabolism relationship, a new derivative 5a was achieved. Compound 5a showed 100-fold increased potency in the ability to reduce pHIB to pH 6.0 and similarly improved mycobactericidal activity compared with 1 against both Mycobacterium bovis-BCG and Mtb. Compound 5a possessed improved metabolic stability in human liver microsomes and hepatocytes, lower cytotoxicity, higher selectivity index, and similar pKa value to natural 1. This study introduces a novel scaffold to an old drug, resulting in improved mycobactericidal activity through decreasing pHIB, and may contribute to the critical search for new agents to overcome drug resistance and persistence in the treatment of tuberculosis.

Novel diphenylmethyl compounds having mycobacterium tuberculosis inhibitory activity

The invention relates to novel diphenylmethyl derivatives having mycobacterium tuberculosis inhibitory activity and a preparation method thereof and particularly relates novel diphenylmethyl derivatives having activity for inhibiting replicative and non-replicating mycobacterium tuberculosis and a preparation method thereof. In particular, the invention relates to compounds shown in the formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described in the specification. The invention also relates to the preparation method of the compounds and their pharmaceutical compositions and a use of the compounds in preparation of drugs for treating mycobacterium tuberculosis infection-caused diseases.